SUMMARY
Background Several circulating biomarkers are reported to be associated with diabetic retinopathy (DR). However, their relative contributions to DR compared to known risk factors, such as hyperglycemia, hypertension, and hyperlipidemia, remain unclear. In this data driven study, we used novel models to evaluate the associations of over 400 laboratory parameters with DR.
Methods We performed an environment-wide association study (EWAS) of laboratory parameters available in National Health and Nutrition Examination Survey (NHANES) 2007-8 in individuals with diabetes with DR as the outcome (test set). We employed independent variable (‘feature’) selection approaches, including parallelized univariate regression modeling, Principal Component Analysis (PCA), penalized regression, and RandomForest™. These models were replicated in NHANES 2005-6 (replication set).
Findings The test and replication set consisted of 1025 and 637 individuals with available DR status and laboratory data respectively. Glycohemoglobin (HbA1c) was the strongest risk factor for DR. Our PCA-based approach produced a model that incorporated 18 principal components (PCs) that had AUC 0.796 (95% CI 0.761-0.832), while penalized regression identified a 9-feature model with 78.51% accuracy and AUC 0.74 (95% CI 0.72-0.77). RandomForest™ identified a 31-feature model with 78.4% accuracy and AUC 0.71 (95% CI 0.65-0.77). On grouping the selected variables in our RandomForest™, hyperglycemia alone achieved AUC 0.72 (95% CI 0.68-0.76). The AUC increased to 0.84 (95% CI 0.78-0.9) when the model also included hypertension, hypercholesterolemia, hematocrit, renal and liver function tests.
Interpretation All models showed that the contributions of established risk factors of DR especially hyperglycemia outweigh other laboratory parameters available in NHANES.
RESEARCH IN CONTEXT What is already known about this subject?
▪ There are >500 publications that report associations of candidate circulating biomarkers with diabetic retinopathy (DR).
▪ Although hyperglycemia, hypertension, and hyperlipidemia are established risk factors, they do not always explain the variance of this complication in people with diabetes; DR also shares risk factors with other diabetes complications including markers of renal and cardiovascular disease.
▪ ‘Holistic’ studies that quantify risk across all of these parameters combined are lacking.
What is the key question?
▪ It is unclear whether risk models for DR may be improved by adding some of these reported biomarkers - there is an unmet need to systematically evaluate as many circulating biomarkers as possible to help rank their associations with DR.
What are the new findings?
▪ We show that hyperglycemia is the strongest risk factor across all models.
▪ We stratified the rest of the highest ranked parameters into groups related to diabetes control, renal and liver function, and hematocrit changes.
How might this impact on clinical practice in the foreseeable future?
▪ The importance of focusing on parameters beyond hyperglycemia control to reduce risk of progression from diabetes to DR is emphasized.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by Global Challenges Research Fund and UK Research and Innovation through the Medical Research Council grant number MR/P027881/1. The research was supported] by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
n/a
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available from The National Health and Nutrition Examination Survey (NHANES - https://wwwn.cdc.gov/Nchs/Nhanes/)
